Viruses and their uses in nanotechnology

Drug Development Research

Volumn 67, Issue 1, 2006, Pages 23-41

  Singh, Pratik ^a   Gonzalez, Maria J ^a   Manchester, Marianne ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Nanoparticles; Nanotechnology AI47823|CA112075|NO1 CO27181; Virus; VLP

Indexed keywords

ADENOVIRUS VECTOR; AMINOBENZOIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BIOMATERIAL; CAPSID PROTEIN; CONTRAST MEDIUM; CRM 107; CYCLODEXTRIN; CYSTEINE; DENDRIMER; DIPHTHERIA TOXIN; DOXORUBICIN; FOLIC ACID; GADOLINIUM; HAPTEN; MACROGOL; METHOTREXATE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; NUCLEIC ACID; POLYAMIDOAMINE; POLYMER; POLYPEPTIDE; PROTEIN MS2; PROTEIN VP1; PROTEIN VP2; QUANTUM DOT; RIBONUCLEOPROTEIN; SULFOSUCCINIMIDYL (4 IODOACETYL)AMINOBENZOATE; TRANSFERRIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; BACTERIOPHAGE M13; BIOCONJUGATION; BIOMEDICINE; CANCER; CHEMISTRY; CLINICAL TRIAL; COWPEA CHLOROTIC MOTTLE VIRUS; COWPEA MOSAIC VIRUS; DNA VIRUS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; ELECTRONICS; FLOCK HOUSE VIRUS; GEOMETRY; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; LIVER TOXICITY; MATERIALS; MS2 VIRUS; NANOTECHNOLOGY; NEUTRON CAPTURE THERAPY; NONHUMAN; PAPILLOMA VIRUS; PHAGE DISPLAY; PLANT VIRUS; POLYOMA VIRUS; REVIEW; RNA VIRUS; TOBACCO MOSAIC VIRUS; VIRUS CAPSID; VIRUS PARTICLE;

EID: 33644641399     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20064     Document Type: Review

References (173)

1. Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CM, Thies MJ, Walter J, Weigand M, Woith DC, Hess J, Reiser CO. 2004. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 279:27410-27421.
2. Ahlquist P. 1992. Bromovirus RNA replication and transcription. Curr Opinion in Genet Dev 2:71-76.
3. Aina OH, Sroka TC, Chen ML, Lam KS. 2002. Therapeutic cancer targeting peptides. Biopolymers 66:184-199.
4. Ammon C, Meyer SP, Schwarzfischer L, Krause SW, Andreesen R, Kreutz M. 2000. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 100:364-369.
5. Arap W, Pasqualini R, Ruoslahti E, 1998a. Cancer treatment by-targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380.
6. Arap W, Pasqualini R, Ruoslahti E. 1998b. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 10:560-565.
7. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E. 2002. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 99:1527-1531.
8. Arora PS, Kirshenbaum K. 2004. Nano-tailoring: stitching alterations on viral coats. Chem Biol 11:418-420.
9. Ashok A, Atwood WJ. 2003. Contrasting roles of endosomal pH and the cytoskeleton in infection of human glial cells by JC virus and simian virus 40. J Virol 77:1347-1356.
10. Atkinson SF, Bettinger T, Seymour LW, Behr JP, Ward CM. 2001. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J Biol Chem 276:27930-27935.
11. Azios N, Romero F, Denton M, Doherty J, Clinton G, 2001. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 20:5199-5209.
12. Bachmann MF, Hengartner H, Zinkernagel RM. 1995. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol 25:3445-3451.
13. Barry MA, Dower WJ, Johnston SA. 1996. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 2:299-305.
14. Becker A, Riefke B, Ebert B, Sukowski U, Rinneberg H, Semmler W, Licha K. 2000. Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin. Photochem Photobiol 72:234-241.
15. Beijerinck MW. 1898. Concerning a contagium vivum fluidum as a cause of the spot-disease of tobacco leaves. Verh Akad Wetensch 6:3-21.
16. Bellocq N, Pun S, Jensen GS, Davis ME. 2003. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconj Chem 14:1122-1132.
17. Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG. 2002. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther 6:287-297.
18. Bierne H, Cossart P. 2002. InlB, a surface protein of Listeria monocytogenes that behaves as an invasin and a growth factor. J Cell Sci 115:3357-3367.
19. Bothner B, Taylor D, Jun B, Lee KK, Siuzdak G, Schlutz CP, Johnson JE. 2005. Maturation of a tetravirus capsid alters the dynamic properties and creates a metastable complex. Virology 334:17-27.
20. Bousarghin L, Touze A, Combita-Rojas AL, Coursaget P. 2003. Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J Gen Virol 84:157-164.
21. Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL. 1987. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev 98:95-114.
22. Bridges KR, Smith BR. 1985. Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells. J Clin Invest 76:913-918.
23. Brown WL, Mastico RA, Wu M, Heal KG, Adams CJ, Murray JB, Simpson JC, Lord JM, Taylor-Robinson AW, Stockley PG. 2002. RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45:371-380.
24. Brumfield S, Willits D, Tang L, Johnson JE, Douglas T, Young M. 2004. Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J Gen Virol 85:1049-1053.
25. Bubendorf L, Nocito A, Moch H, Sauter G. 2001. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72-79.
26. Cargile BJ, McLuckey SA, Stephenson JLJ. 2001. Identification of bacteriophage MS2 coat protein from E. coli lysates via ion trap collisional activation of intact protein ions. Anal Chem 73:1277-1285.
27. Chatterji A, Ochoa W, Paine M, Ratna BR, Johnson JE, Lin T. 2004a. New Addresses on an addressable virus nanoblock: uniquely reactive lysine residues on cowpea mosaic virus. Chem and Biol 11:855-863.
28. Chatterji A, Ochoa W, Shamieh L, Salakian SP, Wong SM, Clingon G, Ghosh P, Lint T, Johnson J. 2004b. Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem 15:807-813.
29. Chatterji A, Ochoa WF, Ueno T, Lin T, Johnson JE. 2005. A virus-based nanoblock with tunable electrostatic properties. Nano Lett 5:597-602.
30. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R. 2004. Design and validation of a bifunctional ligand display system for receptor targeting. Chem Biol 11:1081-1091.
31. Chen Z, Stauffacher C, Johnson JE. 1990. Capsid structure and RNA packaging in comovirus. Semin Virol 1:453-466.
32. Choi Y, Baker JRJ. 2005. Targeting cancer cells with DNA-assembled dendrimers: a mix and match strategy for cancer. Cell Cycle 4:669-671.
33. Christ M, Louis B, Stoeckel F, Dieterle A, Grave L, Dreyer D, Kintz J, Ali Hadji D, Lusky M, Mehtali M. 2000. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum Gene Ther 11:415-427.
34. Cleveland S, Buratti E, Jones T, North P, Baralle F, McLain L, McInerney T, Durrani Z, Dimmock N. 2000. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. Virology 266:66-78.
35. Combita AL, Touze A, Bousarghin L, Sizaret PY, Munoz N, Coursaget P. 2001. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 204:183-188.
36. Cotter MJ, Muruve DA. 2005. The induction of inflammation by adenovirus vectors used for gene therapy. Front Biosci 10:1098-1105.
37. Cwirla SE, Peters EA, Barrett RW, Dower WJ. 1990. Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 87:6378-6382.
38. Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. 2001. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 13:633-641.
39. Dalsgaard K, Uttenthal A, Jones TD, Xu F, Merryweather A, Hamilton WD, Langeveld JP, Boshuizen RS, Kamstrup S, Lomonossoff GP, Porta C, Vela C, Casal JI, Meloen RH, Rodgers PB. 1997. Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol 15:248-252.
40. Day PM, Lowy DR, Schiller JT 2003. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307:1-11.
41. Dessens JT, Lomonossoff GP. 1993. Cauliflower mosaic virus 35S promoter-controlled DNA copies of cowpea mosaic virus RNAs are infectious on plants. J Gen Virol 74:889-892.
42. Douglas JT, Young D. 1998. Host-guest encapsulation of materials by assembled virus protein cages. Nature 393:152-155.
43. Douglas T, 2003. Materials science. A bright, bio-inspired future. Science 200:1192-1193.
44. Drobni P, Naslund J, Evander M. 2004. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res 64:63-68.
45. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. 1999. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038.
46. Enders JF, Weller TH, Robbins FC. 1949. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various humen embryonic tissues. Science 109:85-87.
47. Engler H, Machemer T, Philopena J, Wen Sf, Quijano E, Ramachandra M, Tsai V, Ralston R. 2004. Acute hepatoxocity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328:52-61.
48. Flenniken ML, Liepold LO, Crowley BE, Willits DA, Young MJ, Douglas T 2005. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun (Camb) 28:447-449.
49. Forstova J, Krauzewicz N, Sandig V, Elliott J, Palkova ZS, Strauss M, Griffin BE. 1995. Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells.
50. Gabizon A, Horowitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, Qazen MM, Zalipsky S. 1999. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 10:289-298.
51. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. 2004. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177-1192.
52. Giblin MF, Veerendra B, Smith CJ. 2005. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer. In Vivo 19:9-29.
53. Gleiter S, Lilie H. 2003. Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles. Biol Chem 384:247-255.
54. Goldmann C, Petty H, Frye S, Ast O, Ebitsch S, Jentsch KDK, FJ, Weber F, Trebst C, Nisslein T, Hunsmann G, Weber T, Luke W 1999. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 73:4465-4469.
55. Goldmann C, Stolte N, Nisslein T, Hunsmann G, Luke W, Petry H. 2000. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J Virol Methods 90:85-90.
56. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. 2000. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6:1949-1957.
57. Graff A, Sauer M, Van Gelder P, Meier W. 2002. Virus-assisted loading of polymer nanocontainer. Proc Natl Acad Sci USA 99:5064-5068.
58. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, Hermiston T, Ulbrich K, Fisher KD, Seymour LW. 2004. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 11:1256-1263.
59. Gupta SS, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG. 2005. Accelerated bioorthogonal cojugation: A practical method for ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconj Chem 16:1572-1579.
60. Hamley IW. 2003. Nanotechnology with soft materials. Angew Chem Int Ed 42:1692-1712.
61. Heath WR, Carbone FR. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19:47.
62. Henning P, Andersson KM, Frykholm K, Ali A, Magnusson MK, Nygren PA, Granio O, Hong SS, Boulanger P, Lindholm L. 2005. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther 12:211-224.
63. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. 2002. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 13:129-141.
64. Hogemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP 2003. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5:495-506.
65. Hooker JM, Kovacs EW, Francis MB. 2004. Interior surface modification of bacteriophage MS2. J Am Chem Soc 126:3718-3719.
66. Houghten RA, Pinilla C, Blondelle SE, Appel JR, Dooley CT, Cuervo JH. 1991. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 354:84-86.
67. Huang A, Bruce A, Pardoll D, Levitsky H. 1996. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 4:349-355.
68. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL. 1993. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 156:212-217.
69. Ivanovska IL, de Pablo PJ, Ibarra B, Sgalari G, MacKintosh FC, Carrascosa JL, Schmidt CF, Wuite GJ. 2004. Bacteriophage capsids: tough nanoshells with complex elastic properties. Proc Natl Acad Sci USA 101:7600-7605.
70. Jondal M, Schirmbeck R, Reimann J. 1996. MHC class I-restricted CTL responses to exogenous antigens. Immunity 5:295-302.
71. Kawakami Y, Fujita T, Matsuzaki Y, Sakurai T, Tsukamoto M, Toda M, Sumimoto H. 2004. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95:784-791.
72. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. 1998. In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol 72:10298-10300.
73. Kickhoefer VA, Garcia Y, Mikyas Y, Johansson E, Zhou JC, Raval-Fernandes S, Minoofar P, Zink JI, Dunn B, Stewart PL, Rome LH. 2005. Engineering of vault nanocapsules with enzymatic and fluorescent properties. Proc Natl Acad Sci USA 102:4348-4352.
74. Klem MT, Willits D, Young M, Douglas T. 2003. 2-D array formation of genetically engineered viral cages on au surfaces and imaging by atomic force microscopy. J Am Chem Soc 125:10806-10807.
75. Knipe DM. 1996. Virus host-cell interactions. In: Fields BN, Knipe DM, Howley PM, Chanock Rm, Melnick JL, Monath TP, Reizman B, Straus SE, editors. Field's Virology. Third edition. Philadelphia: Lippincott-Raven. p 273-300.
76. Komagome R, Sawa H, Suzuki T, Suzuki Y, Tanaka S, Atwood WJ, Nagashima K. 2002. Oligosaccharides as receptors for JC virus. J Virol 76:12992-13000.
77. Koo M, Bendahmane M, Lettieri GA, Paoletti AD, Lane TE, Fitchen JH, Buchmeier MJ, Beachy RN. 1999. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci USA 96:7774-7779.
78. Kovacsovics-Bankowski M, Rock K. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243-246.
79. Kratz F, Beyer U, Roth T, Tarasova N, Collery P, Lechenault F, Cazabat A, Schumacher P, Unger C, Falken U. 1998. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J Pharm Sci 87:338-346.
80. Kratz F, Roth T, Fichiner I, Schumacher P, Fiebig HH, Unger C. 2000. In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model. J Drug Target 8:305-318.
81. Lam KS. 1997. Application of combinatorial library methods in cancer research and drug discovery. Anticancer Drug Des 12:145-167.
82. Landon LA, Deutscher SL. 2003. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 90:509-517.
83. Leamon CP, Pastan I, Low PS. 1993. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem 268:24847-24854.
84. Lee RJ, Low PS. 1994. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198-3204.
85. Lee SW, Mao C, Flynn CE, Belcher AM. 2002. Ordering of quantum dots using genetically engineered viruses. Science 296:892-895.
86. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT. 2001. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166:5346-5355.
87. Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT. 2003. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 106:231-237.
88. Levine A. 2001. Origins of virology. In: Knipe D, Howley P, editors. Fundamental virology. Philadelphia: Lippincott Williams and Wilkins. p 3-18.
89. Li H, Sun H, Qian ZM. 2002. The role of the transferrin-transferrin- receptor system in drug delivery and targeting. Trends Pharmacol Sci 23:206-209.
90. Lin T, Chen Z, Usha R, Stauffacher C, Dai J, Schmidt T, Johnson JE. 1999. The refined crystal structure of cowpea mosaic virus at 2.8 A resolution. Virology 265:20-34.
91. Lu Y, Low PS. 2002. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675-693.
92. Lu Y, Sega E, Leamon CP, Low PS. 2004. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 56:1161-1176.
93. Lu Y, Sega E, Low PS. 2005. Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer 116:710-719.
94. Mao C, Flynn CE, Hayhurst A, Sweeney RY, Qi J, Georgiou G, Iverson B, Belcher AM. 2003. Viral assembly of oriented quantum dot nanowires. Proc Natl Acad Sci USA 100:6946-6951.
95. Mao C, Solis DJ, Reiss BD, Kottmann ST, Sweeney RY, Hayhurst A, Georgiou G, Iverson B, Belcher AM. 2004. Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires. Science 303:213-217.
96. Marvin DA, Hale RD, Nave C, Helmer-Citterich M. 1994. Molecular models and structural comparisons of native and mutant class I filamentous bacteriophages Ff (fd, f1, M13), If1 and IKe. J Mol Biol 235:260-286.
97. Maxfield FR, McGraw TE. 2004. Endocytic recycling. Nat Rev Mol Cell Biol 5:121-132.
98. McInerney TL, Brennan FR, Jones TD, Dimmock NJ. 1999. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine 17:1359-1368.
99. Medintz IL, Sapsford KE, Konnert JH, Chatterji A, Lin T, Johnson JE, Mattoussi H. 2005. Decoration of discretely immobilized cowpea mosaic virus with luminiscent quantum dots. Langmuir 21:5501-5510.
100. Merle E, Rose RC, LeRoux L, Moroianu J. 1999. Nuclear import of HPV11 L1 capsid protein is mediated by karyopherin alpha2beta1 heterodimers. J Cell Biochem 74:628-637.
101. Modelska A, Dietzschold B, Sleysh N, Fu ZF, Steplewski K, Hooper DC, Koprowski H, Yusibov V. 1998. Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci USA 95:2481-2485.
102. Montross L, Watkins S, Moreland RB, Mamon H, Caspar DL, Garcea RL. 1991. Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J Virol 65:4991-4998.
103. Mori T. 2004. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des 10:2335-2343.
104. Moron G, Rueda P, Casal I, Leclerc C. 2002. CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 195:1233-1245.
105. Moron VG, Rueda P, Sedlik C, Leclerc C. 2003. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 171:2242-2250.
106. Muruve DA. 2004. The innate immune response to adenovirus vectors. Hum Gene Ther 15:1157-1166.
107. Nettelbeck DM, Rivera AA, Kupsch J, Dieckmann D, Douglas JT, Kontermann RE, Alemany R, Curiel DT. 2004. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 108:136-145.
108. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. 2004. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 95:613-626.
109. Peabody DS. 2003. A viral platform for chemical modification and multivalent display. J Nanobiotech 1:5.
110. Pelkmans L, Kartenbeck J, Helenius A. 2001. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3:473-483.
111. Pelkmans L, Burli T, Zerial M, Helenius A. 2004. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell 118:767-780.
112. Pho MT, Ashok A, Atwood WJ. 2000. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 74:2288-2292.
113. Pickett GG, Peabody DS. 1993. Encapsidation of heterologous RNAs by bacteriophage MS2 coat protein. Nucleic Acids Res 21:4621-4626.
114. Porta C, Spall VE, Findlay KC, Gergerich RC, Farrance CE, Lomonossoff G. 2003. Cowpea mosaic virus-based chimeras. Effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses. Virology 310:50-63.
115. Portney NG, Singh K, Chaudhary S, Destito G, Schneemann A, Manchester M, Ozkan M. 2005. Organic and inorganic nanoparticle hybrids. Langmuir 21:2098-2103.
116. Qian Z, Li H, Sun H, Ho K. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharm Rev 54:561-587.
117. Qu Q, Sawa H, Suzuki T, Semba S, Henmi C, Okada Y, Tsuda M, Tanaka S, Atwood WJ, Nagashima K. 2004. Nuclear entry mechanism of the human polyomavirus JC virus-like particle: role of importins and the nuclear pore complex. J Biol Chem 279:27735-27742.
118. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, Baker JR Jr. 2002. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19:1310-1316.
119. Rae CR, Khor IW, Wang Q, Destito G, Gonzalez MJ, Singh P, Thomas D, Estrada MN, Powell E, Finn MG, Manchester M. 2005. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343:224-235.
120. Raja KS, Wang Q, Gonzalez MJ, Manchester M, Johnson JE, Finn MG. 2003. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4:472-476.
121. Reid T, Warren R, Kirn D. 2002. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9:979-986.
122. Rein DT, Breidenbach M, Wu H, Han T, Haviv YS, Wang M, Kirby TO, Kawakami Y, Dall P, Alvarez RD, Curiel DT. 2004. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer 111:698-704.
123. Rennermalm A, Li YH, Bohaufs L, Jarstrand C, Brauner A, Brennan FR, Flock JI. 2001. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 19:3376-3383.
124. Rice G, Stedman K, Snyder J, Wiedenheft B, Willits D, Brumfield S, McDermott T, Young MJ. 2001. Viruses from extreme thermal environments. Proc Natl Acad Sci USA 98:13341-13345.
125. Rice G, Tang L, Stedman K, Roberto F, Spuhler J, Gillitzer E, Johnson JE, Douglas T, Young M. 2004. The structure of a thermophilic archaeal virus shows a double-stranded DNA viral capsid type that spans all domains of life. Proc Natl Acad Sci USA 101:7716-7720.
126. Richterova Z, Liebl D, Horak M, Palkova Z, Stokrova J, Hozak PK, Forstova J. 2001. Caveolae are involved in the trafficking of mouse polyomavirus virions and artificial VP1 pseudocapsids toward cell nuclei. J Virol 75:10880-10891.
127. Rieckmann P, Michel U, Kehrl JH. 1994. Regulation of JC virus expression in B lymphocytes. J Virol 68:217-222.
128. Rock KL. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131-137.
129. Ross JF, Chaudhuri PK, Ratnam M. 1994. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73:2432-2443.
130. Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R, Ratnam M. 1999. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85:348-357.
131. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. 2002. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 32:818-825.
132. Ruoslahti E. 2002. Antiangiogenics meet nanotechnology. Cancer Cell 2:97-98.
133. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J. 2004. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 40:1418-1422.
134. 1. Cell 46:895-904.
135. Sando S, Sasaki T, Aoyama Y. 2003. Encapsulation of DNA with neutral glycocluster nanoparticles. A step toward artificial viruses. Nucleic Acids Res 3(Suppl):289-290.
136. Sato Y, Yamauchi N, Takahashi M, Sasaki K, Fukaura J, Neda H, Fujii S, Hirayama M, Itoh Y, Koshita Y, Kogawa K, Kato J, Sakamaki S, Niitsu Y. 2000. In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J 14:2108-2118.
137. Schiedner G, Clemens PR, Volpers C, Kochanek S. 2002. High-capacity gutless adenoviral vectors: technical aspects and applications. Curiel DT, Douglas JT, editors: New York: Academic Press. p 429-442.
138. Schiedner G, Bloch W, Hertel S, Johnston M, Molojavyi A, Dries V, Varga G, Van Rooijen N, Kochanek S. 2003. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 14:1631-1641.
139. Schlick TL, Ding Z, Kovacs EW, Francis MB. 2005. Dual-surface modification of the tobacco mosaic virus. J Am Chem Soc 127:3718-3723.
140. Schmid SL. 1997. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu Rev Biochem 66:511-548.
141. Schmidt U, Gunther C, Rudolph R, Bohm G. 2001. Protein and peptide delivery via engineered polyomavirus-like particles. FASEB J 15:1646-1648.
142. Schneemann A, Young MJ. 2003. Viral assembly using heterologous expression systems and cell extracts. Adv Protein Chem 64:1-36.
143. Shu D, Huang LP, Hoeprich S, Guo P. 2003. Construction of phi29 DNA-packaging RNA monomers, dimers, and trimers with variable sizes and shapes as potential parts for nanodevices. J Nanosci Nanotechnol 3:295-302.
144. Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN. 2001. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28:1555-1565.
145. Singh M. 1999. Transferrin As A targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 5:443-451.
146. Smith GP. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317.
147. Soll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG. 2001. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur J Biochem 268:2828-2837.
148. Speir JA, Munshi S, Wang G, Baker TS, Johnson JE. 1995. Structures of the native and swollen forms of cowpea chlorotic mottle virus determined by X-ray crystallography and cryo electron microscopy. Structure 3:63-78.
149. Staczek J, Bendahmane M, Gilleland LB, Beachy RN, Gilleland HEJ. 2000. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine 18:2266-2274.
150. Stephenson SM, Low PS, Lee RJ. 2004. Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol 387:33-50.
151. Stolz B, Smith-Jones P, Albert R, Weckbecker G, Bruns C. 1999. New somatostatin analogues for radiotherapy of somatostatin receptor expressing tumours. Ital J Gastroenterol Hepatol 1999(Suppl 2):S224-S226.
152. Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, Dumrese T, Kundig TM, Ruedl C, Bachmann M. 2002. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 168:2880-2886.
153. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. 2004. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172:1777-1785.
154. Strable E, Johnson JE, Finn MG. 2004. Natural nanochemical building blocks: icosahedral virus particles organized by attached oligonucleotides. Nano Lett 4:1385.
155. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. 1997. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193-198.
156. Valegård K, Liljas L, Fridborg K, Unge T. 1990. The three-dimensional structure of the bacterial virus MS2. Nature (Lond) 345:36-41.
157. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. 2003. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 63:6864-6869.
158. Wang M, Tsou TH, Chen LS, Ou WC, Chen PL, Chang CF, Fung CY, Chang D. 2004. Inhibition of simian virus 40 large tumor antigen expression in human fetal glial cells by an antisense oligodeoxynucleotide delivered by the JC virus-like particle. Hum Gene Ther 15:1077-1090.
159. Wang Q, Kaltgrad E, Lin T, Johnson J, Finn M. 2002a. Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem Biol 9:805-811.
160. Wang Q, Lin T, Johnson J, Finn M. 2002b. Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem Biol 9:813-819.
161. Wang Q, Chan TR, Hilgraf R, Fokin VV, Sharpless KB, Finn MG. 2003. Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc 125:3192-3193.
162. Weaver M, Laske DW. 2003. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65:3-13.
163. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8:37-44.
164. Wu M, Gunning W, Ratnam M. 1999. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8:775-782.
165. Xu L, Frederik P, Pirollo KF, Tang WH, Rait A, Xiang LM, Huang W, Cruz I, Yin Y, Chang EH. 2002. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 13:469-481.
166. Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, Fukuda H, Kondo A, Ueda M, Seno M, Tanizawa K, Kuroda S. 2003. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature Biotechnol 21:885-890.
167. Yamada T, Ueda M, Seno M, Kondo A, Tanizawa K, Kuroda S. 2004. Novel tissue and cell type-specific gene/drug delivery system using surface engineered hepatitis B virus nano-particles. Curr Drug Targets Infect Disord 4:163-167.
168. Yan M, Peng J, Jabbar IA, Liu X, Filgueira L, Frazer IH, Thomas R. 2004. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 324:297-310.
169. Yang R, Yutzy WHt, Viscidi RP, Roden RB. 2003. Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem 278:12546-12553.
170. Yewdell JW, Norbury CC, Bennink JR. 1999. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8 T-cell responses to infectious agents, tumors, transplants and vaccines. Adv Immunol 73:1.
171. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L. 2005. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113:619-628.
172. Zhang S. 2003. Fabrication of novel biomaterials through molecular self-assembly. Nat Biotechnol 21:1171-1178.
173. Zhao X, Fox JM, Olson NH, Baker TS, Young MJ. 1995. In vitro assembly of cowpea chlorotic mottle virus from coat protein expressed in Escherichia coli and in vitro-transcribed viral cDNA. Virology 207:486-494.